Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics


Neurocrine Biosciences, Inc. (NBIX): $94.10

-1.67 (-1.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NBIX POWR Grades


  • NBIX scores best on the Value dimension, with a Value rank ahead of 92.61% of US stocks.
  • The strongest trend for NBIX is in Value, which has been heading up over the past 31 weeks.
  • NBIX ranks lowest in Momentum; there it ranks in the 5th percentile.

NBIX Stock Summary

  • Neurocrine Biosciences Inc's market capitalization of $9,277,798,097 is ahead of 80.41% of US-listed equities.
  • The price/operating cash flow metric for Neurocrine Biosciences Inc is higher than 85.39% of stocks in our set with a positive cash flow.
  • The volatility of Neurocrine Biosciences Inc's share price is greater than that of merely 12.65% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Neurocrine Biosciences Inc, a group of peers worth examining would be CRUS, UTHR, GPX, DLB, and WWD.
  • Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.

NBIX Valuation Summary

  • In comparison to the median Healthcare stock, NBIX's EV/EBIT ratio is 165.5% higher, now standing at 75.8.
  • Over the past 243 months, NBIX's price/sales ratio has gone down 55.6.
  • Over the past 243 months, NBIX's price/earnings ratio has gone up 52.5.

Below are key valuation metrics over time for NBIX.

Stock Date P/S P/B P/E EV/EBIT
NBIX 2019-12-20 15.0 17.6 479.5 178.7
NBIX 2013-11-06 24.4 4.6 -22.7 -21.2
NBIX 2011-11-11 4.8 6.6 9.8 8.7
NBIX 2007-11-08 38.2 1.6 -4.1 -4.2
NBIX 2003-08-06 30.3 7.2 -16.7 -16.2
NBIX 2002-08-07 26.5 3.8 -27.4 -26.6

NBIX Growth Metrics

  • Its 4 year net cashflow from operations growth rate is now at 717.53%.
  • Its 5 year price growth rate is now at 107.08%.
  • Its 2 year price growth rate is now at 27.63%.
Over the past 30 months, NBIX's revenue has gone up $631,135,000.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 1,045.4 277.6 402
2020-12-31 1,045.9 228.5 407.3
2020-09-30 1,042.01 242.153 93.4
2020-06-30 1,005.604 357.479 204.789
2020-03-31 886.784 302.745 176.527
2019-12-31 788.087 152.054 37.012

NBIX Price Target

For more insight on analysts targets of NBIX, see our NBIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $122.35 Average Broker Recommendation 1.46 (Moderate Buy)

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $94.10 52-week high $126.71
Prev. close $95.77 52-week low $86.02
Day low $93.12 Volume 778,854
Day high $95.47 Avg. volume 961,979
50-day MA $97.04 Dividend yield N/A
200-day MA $98.82 Market Cap 8.90B

Neurocrine Biosciences, Inc. (NBIX) Company Bio


Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.


NBIX Latest News Stream


Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream


Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Immunotoxins Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences,

This report studies the Immunotoxins Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Immunotoxins market segmented by company, region, type and applications []

Jumbo News | July 25, 2021

United States Parkinson''s Disease Market Insights, Epidemiology and Outlook to 2030 | Addex Pharma, AbbVie, Prevail Therapeutics, Denali Therapeutics, Neurocrine Biosciences, and More

DUBLIN, July 23, 2021 /PRNewswire/ -- The

Business Insider Markets | July 23, 2021

Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)

We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of March 31st. In this article, we look at what those funds think of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) based on that […]

Yahoo | July 22, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Yahoo | July 19, 2021

Essential Tremor Treatment Market Growth 2021-2026: Merz Pharma GmbH & Co KgaA , Neurocrine Biosciences Inc , Sage Therapeutics Inc

Essential Tremor Treatment Market analysis report is sure to help boost sales and improve return on investment (ROI). The research and analysis carried out in this Essential Tremor Treatment Market report assist clients to forecast investment in an emerging market, expansion of market share or success of a new product with the help of global […]

Tramways Monthly | July 9, 2021

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo -6.17%
3-mo -3.68%
6-mo -15.93%
1-year -25.32%
3-year -12.24%
5-year 87.64%
YTD -1.83%
2020 -10.83%
2019 50.53%
2018 -7.96%
2017 100.49%
2016 -31.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7923 seconds.